The pronounced decline of anti-SARS-CoV-2 spike trimeric IgG and RBD IgG in baseline seronegative individuals six months after BNT162b2 vaccination is consistent with the need for vaccine boosters

Salvagno, Gian Luca; Henry, Brandon Michael; Pighi, Laura; Nitto, Simone De; Gianfilippi, Gianluca; Lippi, Giuseppe

doi:10.1515/cclm-2021-1184

Cited by 28 publications

(31 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A plausible biological explanation supports these findings, wherein the serum levels of anti-SARS-CoV-2 neutralizing antibodies tends to gradually decline over time, and such reduction seems even amplified in older people, as we have recently demonstrated [ 16 ]. The efficacy of COVID-19 vaccines largely depends on anti-SARS-CoV-2 neutralizing antibodies titer, irrespective of the type of vaccine [ 17 ], and COVID-19 vaccine boosters are especially effective to increase the serum levels of these antibodies by over twofold in older people (i.e., aged 65–85 years) compared to younger subjects [ 18 ].…”

Section: Discussionsupporting

confidence: 73%

Efficacy of COVID-19 vaccine booster doses in older people

Mattiuzzi¹,

Lippi

2022

Eur Geriatr Med

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 73%

Efficacy of COVID-19 vaccine booster doses in older people

Mattiuzzi¹,

Lippi

2022

Eur Geriatr Med

Self Cite

View full text Add to dashboard Cite

show abstract

“…A plausible biological explanation supports these findings, wherein the serum levels of anti-SARS-CoV-2 neutralizing antibodies tends to gradually decline over time, and such reduction seems even amplified in older people, as we have recently demonstrated [15]. The efficacy of COVID-19 vaccines largely depends on anti-SARS-CoV-2 neutralizing antibodies titer, irrespective of the type of vaccine [16], and COVID-19 vaccine boosters are especially effective to increase the serum levels of these antibodies by over 2-fold in older people (i.e., aged 65-85 years) compared to younger subjects [17].…”

Section: Discussionsupporting

confidence: 79%

Efficacy of COVID-19 vaccine booster doses in older people

Mattiuzzi¹,

Lippi

2021

Preprint

Self Cite

View full text Add to dashboard Cite

Purpose. We provide here an updated analysis on efficacy of COVID-19 vaccine booster doses in older people (i.e., aged ≥80 years) based on ongoing Italian nationwide COVID-19 vaccination campaign. Methods. Data were obtained from the COVID-19 national integrated surveillance program, made available and regularly updated by the Italian National Institute of Health.Results. Compared to those who completed the COVID-19 vaccination cycle for ≥5 months (n=2.385.897), those receiving booster doses (n=1.549.747) had 75% lower risk of SARS-CoV-2 infection, 82-83% lower risk of COVID-19 hospitalization and ICU admission, and 81% lower risk of death. Administration of COVID-19 vaccine boosters generated also greater protection (between 63-87% higher) against all these same endpoints compared to early completing (i.e., <5 months; n=335.458) a primary COVID-19 vaccination cycle.Conclusions. The administration of COVID-19 vaccine booster doses is advisable for reducing the risk of morbidity and mortality in older people.

show abstract

“…One possible hypothesis explaining the similar waning between HC and DS is the older age of the HC. Indeed, the major impact of age on the maintenance of SARS-CoV2 specific immunity has been widely shown [18][19][20]. However, DS is a chronic condition, characterized by an accelerated immune aging, and an older aged control group can provide an important comparison, in terms of vaccine-induced immunity and memory maintenance.…”

Section: Discussionmentioning

confidence: 99%

Safety and Long-Term Immunogenicity of BNT162b2 Vaccine in Individuals with Down Syndrome

Valentini

Cotugno

Scoppola

et al. 2022

JCM

View full text Add to dashboard Cite

We aimed to evaluate the safety and immunogenicity of the BNT162b2 vaccine in young people with Down syndrome (DS), and to compare their humoral immune response with those of the healthy controls (HC). Individuals with DS and HC received the BNT162b2 vaccine. Longitudinal blood samples were collected on the day of vaccination, twenty-one days after the first dose, seven days after the second dose, and six months after the first dose. Both the local and systemic adverse events reported by participants were mild. Pain at the injection site was the most reported local adverse event, while fever was the systemic adverse event. Humoral responses showed a significant increase of anti-S and anti-S trimeric antibody (Ab) levels after both doses of vaccine in both groups. In comparison with HC, Ab levels in individuals with DS were similar at T21, but significantly lower, both in terms anti-S and anti-S trimeric, at T28 (respectively p = 0.0003 and p = 0.0001). At T180 both groups showed a significant reduction of anti-S trimeric Ab levels compared to T28 (p = 0.0004 and p < 0.0001 for DS and HC, respectively). Individuals with DS exhibit a good humoral response to the BNT162b2 vaccine; however, similarly to in HC, the immune response wanes over time.

show abstract

The pronounced decline of anti-SARS-CoV-2 spike trimeric IgG and RBD IgG in baseline seronegative individuals six months after BNT162b2 vaccination is consistent with the need for vaccine boosters

Cited by 28 publications

References 12 publications

Efficacy of COVID-19 vaccine booster doses in older people

Efficacy of COVID-19 vaccine booster doses in older people

Efficacy of COVID-19 vaccine booster doses in older people

Safety and Long-Term Immunogenicity of BNT162b2 Vaccine in Individuals with Down Syndrome

Contact Info

Product

Resources

About